Humacyte, Inc. (Nasdaq: HUMA) has developed a disruptive
biotechnology platform to deliver universally implantable, bioengineered
human tissues and organs designed to improve the lives of patients
and transform the practice of medicine. Located in Durham, N.C.,
the company was founded in 2004 by Laura Niklason, MD, Ph.D., a
world leader in tissue engineering and the Chief Executive Officer of
Humacyte, along with Drs. Juliana Blum and Shannon Dahl.